Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

(Loss)/Earnings per Share - Schedule of (Loss)/Earnings Per Share (Details)

v3.22.2
(Loss)/Earnings per Share - Schedule of (Loss)/Earnings Per Share (Details) - USD ($)
12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings per share [line items]    
(Loss)/profit for the year attributable to Virax $ (1,708,827) $ (650,984)
Class A    
Earnings per share [line items]    
Basic (loss)/earnings per share attributable to Virax $ (0.67) $ (0.41)
Diluted (loss)/earnings per share attributable to Virax (0.67) (0.41)
Class B    
Earnings per share [line items]    
Basic (loss)/earnings per share attributable to Virax (0.24) (0.79)
Diluted (loss)/earnings per share attributable to Virax $ (0.24) $ (0.79)